Product Images Finasteride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Finasteride NDC 60687-428 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
100 UD Carton
This is a medication packaging for Finasteride Tablets, USP with NDC number 60667-428-01 and 60687-428-01 respectively. It contains 100 tablets in a pack of 10 x 10 tablets. The rest of the text seems to be errors and not readable.*
50 UD Carton
This is a description of the drug Finasteride, which is available in a 50 tablet pack for Rx-only use. The drug should not be used by women or children, and women who may be pregnant should avoid using it. Each film-coated tablet contains 0.97mg of the active ingredient. The suggested dosage for adults is 1 to 5 mg per day. The drug should be stored between 20°C to 25°C and protected from heat. The drug product is manufactured and distributed by Aurobindo Pharma USA Inc., and the packaging is done by Richmond & Packaging Inc.*
AHP 428 01 65
Blister
This appears to be a list of different variations of Finasteride tablets in different doses and under different brand names, with associated lot numbers and expiry dates for each.*
Figure 1
Figure 2
This appears to be a part of a research study that includes a graph (Figure 2) indicating the percentage of patients, who underwent surgery for BPH, over a period of observation time (in months) in two groups - those who received Finasteride and those who received a placebo. The graph shows that the percentage of patients who had surgery for BPH in the Finasteride group was lower than the percentage in the placebo group. The text also includes some numerical data related to the number of events and the number of patients at risk in both the groups.*
Figure 3
This is a graph showing the percentages of patients who developed acute urinary retention over a period of 24 months. Two groups are being compared - placebo group and Finasteride group. At the end of 24 months, 16% of patients in the placebo group developed acute urinary retention while only 2% of patients in the Finasteride group developed it. The graph also shows the number of patients at risk over time and the number of events (urinary retention) that occurred at different time points.*
Figure 4
Figure 5
This is a graph showing the Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group. The percent of people with an event is plotted on the Y-axis while the years from randomization are plotted on the X-axis.*
Structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.